The Korea Fund, Inc.

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2026 (Unaudited)

 

Investments

   Shares      Value ($)  

COMMON STOCKS—99.2%

 

Aerospace & Defense—2.9%

 

Hanwha Aerospace Co. Ltd.

     3,900        3,325,556  

Korea Aerospace Industries Ltd.

     25,500        2,882,668  
     

 

 

 
        6,208,224  
     

 

 

 

Automobile Components—1.6%

 

Hankook Tire & Technology Co. Ltd.

     53,400        1,965,696  

Hyundai Mobis Co. Ltd.

     6,100        1,573,923  
     

 

 

 
        3,539,619  
     

 

 

 

Automobiles—6.5%

 

Hyundai Motor Co.

     18,200        5,606,699  

Hyundai Motor Co. (Preference)

     16,500        2,612,146  

Kia Corp.

     57,500        5,677,033  
     

 

 

 
        13,895,878  
     

 

 

 

Banks—6.8%

 

BNK Financial Group, Inc.

     169,000        2,049,590  

KB Financial Group, Inc.

     65,400        6,420,348  

Shinhan Financial Group Co. Ltd.

     101,600        6,055,498  
     

 

 

 
        14,525,436  
     

 

 

 

Biotechnology—2.2%

 

Alteogen, Inc.

     4,700        1,066,034  

Hugel, Inc.*

     10,600        1,708,313  

Kolon TissueGene, Inc., Receipts (United States)*

     26,350        1,913,020  
     

 

 

 
        4,687,367  
     

 

 

 

Broadline Retail—0.6%

 

Shinsegae, Inc.

     6,000        1,233,869  
     

 

 

 

Building Products—0.8%

 

Sung Kwang Bend Co. Ltd.

     71,500        1,701,812  
     

 

 

 

Capital Markets—1.6%

 

Daou Technology, Inc.

     53,900        1,566,914  

Korea Investment Holdings Co. Ltd.

     13,150        1,834,593  
     

 

 

 
        3,401,507  
     

 

 

 

Chemicals—3.0%

 

Hansol Chemical Co. Ltd.

     10,104        1,733,050  

Kumho Petrochemical Co. Ltd.

     22,500        1,795,943  

LG Chem Ltd.

     14,100        2,882,030  
     

 

 

 
        6,411,023  
     

 

 

 

Construction & Engineering—2.1%

 

HDC Hyundai Development Co-Engineering & Construction

     68,449        939,707  

Hyundai Engineering & Construction Co. Ltd.

     35,500        3,465,842  
     

 

 

 
        4,405,549  
     

 

 

 

Electric Utilities—0.9%

 

Korea Electric Power Corp.

     68,000        1,933,263  
     

 

 

 

Electrical Equipment—2.6%

 

Hyosung Heavy Industries Corp.

     1,850        3,123,857  

LG Energy Solution Ltd.*

     8,800        2,407,426  
     

 

 

 
        5,531,283  
     

 

 

 

Electronic Equipment, Instruments & Components—4.0%

 

Daeduck Electronics Co. Ltd.

     23,500        1,219,798  

IsuPetasys Co. Ltd.

     23,750        1,645,793  

Samsung Electro-Mechanics Co. Ltd.

     19,500        5,586,929  
     

 

 

 
        8,452,520  
     

 

 

 

Entertainment—0.9%

 

JYP Entertainment Corp.

     45,300        1,869,060  
     

 

 

 

Food Products—0.4%

 

NongShim Co. Ltd.

     3,301        808,385  
     

 

 

 

Health Care Equipment & Supplies—0.8%

 

Classys, Inc.

     53,200        1,807,808  
     

 

 

 

Hotels, Restaurants & Leisure—0.4%

 

Lotte Tour Development Co. Ltd.*

     79,500        933,204  
     

 

 

 

Industrial Conglomerates—6.2%

 

Samsung C&T Corp.

     24,800        4,346,399  

SK Square Co. Ltd.*

     15,500        5,103,414  

SK, Inc.

     18,500        3,803,483  
     

 

 

 
        13,253,296  
     

 

 

 

Interactive Media & Services—2.1%

 

Kakao Corp.

     19,400        598,922  

NAVER Corp.

     28,700        3,907,461  
     

 

 

 
        4,506,383  
     

 

 

 

Life Sciences Tools & Services—2.5%

 

LigaChem Biosciences, Inc.*

     16,400        2,146,067  

Samsung Biologics Co. Ltd.*(a)

     3,100        3,177,085  
     

 

 

 
        5,323,152  
     

 

 

 

Machinery—3.1%

 

HD Hyundai Heavy Industries Co. Ltd.

     13,300        4,260,257  

MNC Solution Co. Ltd.

     36,000        2,322,977  
     

 

 

 
        6,583,234  
     

 

 

 

Oil, Gas & Consumable Fuels—1.3%

 

S-Oil Corp.*

     40,300        2,763,414  
     

 

 

 

Personal Care Products—0.6%

 

Kolmar Korea Co. Ltd.*

     26,900        1,386,915  
     

 

 

 

Pharmaceuticals—1.0%

 

Hanmi Pharm Co. Ltd.

     5,900        2,106,535  
     

 

 

 

Semiconductors & Semiconductor Equipment—20.1%

 

Eugene Technology Co. Ltd.

     27,300        2,077,180  

PSK, Inc.

     27,500        1,526,839  

SK hynix, Inc.

     69,200        39,261,667  
     

 

 

 
        42,865,686  
     

 

 

 

Technology Hardware, Storage & Peripherals—24.2%

 

Samsung Electronics Co. Ltd.

     385,070        45,038,323  

Samsung Electronics Co. Ltd. (Preference)

     80,700        6,514,394  
     

 

 

 
        51,552,717  
     

 

 

 

TOTAL COMMON STOCKS
(COST $111,975,282)

 

     211,687,139  
  

 

 

 

Total Investments—99.2% (Cost $111,975,282)

 

     211,687,139  

Other Assets Less Liabilities—0.8%

 

     1,636,642  
  

 

 

 

Net Assets—100.0%

 

     213,323,781  
  

 

 

 
 

Percentages indicated are based on net assets.


The Korea Fund, Inc.

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2026 (Unaudited) (continued)

 

Preference    A special type of equity investment that shares in the earnings of the company, has limited voting rights, and may have a dividend preference. Preference shares may also have liquidation preference.
(a)    Security exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. Regulation S applies to securities offerings that are made outside of the United States and do not involve direct selling efforts in the United States and as such may have restrictions on resale.
*    Non-income producing security.


The Korea Fund, Inc.

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2026 (Unaudited) (continued)

 

A. Valuation of Investments – Investments are valued in accordance with U.S. generally accepted accounting principles (“GAAP”) and the Fund’s valuation policies set forth by, and under the supervision and responsibility of, the Board of Trustees of the Trust (the “Board”), which established the following approach to valuation, as described more fully below: (i) investments for which market quotations are readily available shall be valued at their market value and (ii) all other investments for which market quotations are not readily available shall be valued at their fair value as determined in good faith by the Board.

Under Section 2(a)(41) of the Investment Company Act of 1940 Act, the Board is required to determine fair value for securities that do not have readily available market quotations. Under SEC Rule 2a-5 (Good Faith Determinations of Fair Value), the Board may designate the performance of these fair valuation determinations to a valuation designee. The Board has designated the Adviser as the “Valuation

Designee” to perform fair valuation determinations for the Fund on behalf of the Board subject to appropriate oversight by the Board. The Adviser, as Valuation Designee, leverages the J.P. Morgan Asset Management Americas Valuation Committee (“AVC”) to help oversee and carry out the policies for the valuation of investments held in the Funds. The Adviser, as Valuation Designee, remains responsible for the valuation determinations. This oversight by the AVC includes monitoring the appropriateness of fair values based on results of ongoing valuation oversight including, but not limited to, consideration of macro or security specific events, market events, and pricing vendor and broker due diligence. The Administrator is responsible for discussing and assessing the potential impacts to the fair values on an ongoing basis, and, at least on a quarterly basis, with the AVC and the Board.

Equities and other exchange-traded instruments are valued at the last sale price or official market closing price on the primary exchange on which the instrument is traded before the net asset values (“NAV”) of the Fund are calculated on a valuation date.

Certain foreign equity instruments are valued by applying international fair value factors provided by an approved Pricing Service. The factors seek to adjust the local closing price for movements of local markets post-closing, but prior to the time the NAVs are calculated.

Valuations reflected in this report are as of the report date. As a result, changes in valuation due to market events and/or issuer-related events after the report date and prior to issuance of the report are not reflected herein.

The various inputs that are used in determining the valuation of the Fund’s investments are summarized into the three broad levels listed below.

 

   

Level 1 — Unadjusted inputs using quoted prices in active markets for identical investments.

 

   

Level 2 — Other significant observable inputs including, but not limited to, quoted prices for similar investments, inputs other than quoted prices that are observable for investments (such as interest rates, prepayment speeds, credit risk, etc.) or other market corroborated inputs.

 

   

Level 3 — Significant inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Fund’s assumptions in determining the fair value of investments).

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input, both individually and in the aggregate, that is significant to the fair value measurement. The inputs or methodology used for valuing instruments are not necessarily an indication of the risk associated with investing in those instruments.

The following table represents each valuation input as presented on the Schedule of Portfolio Investments:

 

     Level 1
Quoted prices
     Level 2
Other significant
observable
inputs
     Level 3
Significant
unobservable
inputs
     Total  

Total Investments in Securities(a)

   $      $ 211,687,139      $      $ 211,687,139  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(a)

Please refer to the schedule of portfolio investments for specifics of portfolio holdings.